Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC

Cardiff Oncology, Inc.

2025-Q3 EPS reported -$0.58 revenue$350,000

Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.
Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.
Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.
Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.
Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.